Replies to post #260618 on Elite Pharmaceuticals Inc (ELTP)

[Couch]

Sure K - The never missing a quarterly SEC filing, the new accountant position not yet filled, and the Percocet and Norco filing alone says otherwise. Next

[NASDAQ2020]

14 Pathways to DollarLand

1.) First ever Immediate Release ADF labeled opiod with ORAL AD Labeling
using the Pharmacological Approach
----------- Reformulated SequestOx™ ----------
2.) First ever generic ER ADF labeled Oxycodone ELI-201
3.) First ever generic Embeda®
4.) First ever generic Troxyca®
5.) A couple $50-100 million dollar ANDAs
6.) First ever Abuse Deterrent generic of reformulated OxyContin®
7.) File Huge Blockbuster Undisclosed NDA
8.) Lauch All four SunGen generics ($3 Billion combined markets)
9.) Buyout/Acquisition
10.)Mega Partnership !!!!
11.)Uplisting to NASDAQ exchange
12.) First ever ER opiod with out food restrictions
13.) Start PH III trials for the first ever 24 hour
14.) Reformulated Opana ER

ELTP

[dr_lowenstein]

there is little accountability and material weakness in controls: (from the last 10Q)



As of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation and the material weaknesses described below, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were not effective such that the information relating to our Company required to be disclosed in our SEC reports (i) is not recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (ii) is not accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis.



The material weaknesses relate to inadequate segregation of duties in our financial reporting process and disclosure controls and procedures and internal controls over financial reporting of complex accounting issues.